Based on our previous findings and existing evidence, we hypothesized that increased ANRIL expression may play a role in the chemoresistance of osteosarcoma to cisplatin and doxorubicin and that ANRIL knockdown may lead to increased chemosensitivity to those agents. Here, CDKN2B-AS1 is linked to osteosarcoma.